In recent developments, Roche has featured prominently in the race to develop TIGIT inhibitors for cancer immunotherapy, ...

Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS ...

Volastra Therapeutics, a clinical-stage biotechnology company pioneering first-in-class therapies targeting chromosomal ...

The European voice/vocal biomarker market is positioned for substantial growth, reaching $1.69 billion by 2035 from $335.2 ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Finger-prick blood test accurately detects Alzheimer’s biomarkers, enabling at-home collection and broader research ...

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company ...

YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the ...